Martin Whitman - Third Avenue Management
Holding/activity history for Supernus Pharmaceuticals (SUPN)
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Reported Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026 Q1 | 152,724 | 1.28 | Reduce 19.40% | 0.33 | $51.69 | $7,894,304 | SEC |
| 2025 Q4 | 189,493 | 1.71 | $49.70 | $9,417,802 | SEC | ||
| 2025 Q3 | 189,493 | 1.71 | $48.04 | $9,103,244 | SEC | ||
| 2025 Q2 | 189,493 | 1.23 | $31.52 | $5,972,819 | SEC | ||
| 2025 Q1 | 189,493 | 1.24 | $32.75 | $6,205,896 | SEC | ||
| 2024 Q4 | 189,493 | 1.33 | $36.16 | $6,852,067 | SEC | ||
| 2024 Q3 | 189,493 | 0.97 | Add 0.20% | <0.01 | $31.18 | $5,908,392 | SEC |
| 2024 Q2 | 189,118 | 0.87 | Add 18.41% | 0.14 | $26.75 | $5,058,907 | SEC |
| 2024 Q1 | 159,717 | 0.87 | $34.11 | $5,447,947 | SEC | ||
| 2023 Q4 | 159,717 | 0.76 | Add 37.04% | 0.21 | $28.94 | $4,622,210 | SEC |
| 2023 Q3 | 116,549 | 0.55 | Add 73.79% | 0.23 | $28.08 | $3,272,696 | SEC |
| 2023 Q2 | 67,062 | 0.33 | Add 2,626.10% | 0.32 | $30.06 | $2,015,884 | SEC |
| 2023 Q1 | 2,460 | 0.02 | $36.23 | $89,126 | SEC | ||
| 2022 Q4 | 2,460 | 0.02 | $35.67 | $87,748 | SEC | ||
| 2022 Q3 | 2,460 | 0.02 | $34.15 | $84,000 | SEC | ||
| 2022 Q2 | 2,460 | 0.01 | Buy | 0.01 | $29.27 | $72,000 | SEC |